Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab Plus Carboplatin in BRCA-related Metastatic Breast Cancer

NCT03732391 is registered in ClinicalTrials.gov with CORTESI LAURA as lead sponsor.

NCT NCT03732391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03732391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab Plus Carboplatin in BRCA-related Metastatic Breast Cancer
Lead sponsor
CORTESI LAURA
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2018
Completion date
January 30, 2023
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer